AzTrials
AzTrials

Bone LossNCT04402671

Lateral Ridge Augmentation Using Cross-linked or Non-cross-linked Collagen Membrane

A study testing non-cross-linked porcine skin collagen membrane and glutaraldehyde cross-linked bovine collagen membrane in people with Bone Loss, run by Saint-Joseph University at 1 site in Lebanon.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The objective of the present trial is to test clinically, radiographically and histologically , in a lateral alveolar ridge augmentation model (without simultaneous implant placement) the efficiency in supporting bone formation of a glutaraldehyde cross-linked collagen membrane compared to a non-cross-linked collagen… Read more about this study

Who is it for?
Ages 20 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Bone Loss
What is being tested?
non-cross-linked porcine skin collagen membrane and glutaraldehyde cross-linked bovine collagen membrane
Could I receive a placebo?
No, everyone receives an active treatment
How many people
4 participants
Where
1 siteLebanon
Study dates
1 Mar 2019to 1 Aug 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy patients, non-smokers or smokers<10 cigarettes/day.
  • Age between 20 and 75.
  • Full mouth bleeding score (FmBS) <20 %.
  • Full mouth plaque score (FmPS) <15%.
  • Presence of a residual alveolar ridge with residual bone width < 5 mm and adequate
  • bone height in the maxilla and the mandible.
  • Tooth extraction performed at least 6 weeks before surgery.
  • Presence of enough teeth to support an occlusal stent/radiographic guide.

Who cannot join

  • Systematic diseases.
  • History of radiotherapy in the head and neck region in the last 5 years.
  • Active periodontitis on the remaining teeth.
  • Pregnancy.
  • Allergy to collagen.
  • Intake of medications that may have an effect on bone turnover and mucosal healing (i.e., tetracycline within the last month, steroids within the last 6 months, bisphosphonates or fluorides at bone therapeutic levels, vitamin D and metabolites at therapeutic levels within the last 6 months).

Trial locations and contacts

1 site in 1 country.

Lebanon1 site
  • Mario Haddad

    Beirut, 1200

Other trials in Lebanon

About this study

Official title: Lateral Ridge Augmentation Using Cross-linked or Non-cross-linked Collagen Membrane: a Pilot Randomized Clinical Trial

The objective of the present trial is to test clinically, radiographically and histologically , in a lateral alveolar ridge augmentation model (without simultaneous implant placement) the efficiency in supporting bone formation of a glutaraldehyde cross-linked collagen membrane compared to a non-cross-linked collagen membrane with the use of a composite autograft-xenograft mix prepared in a 1:3 ratio

Read the detailed description

This study is a pilot one, no sample size calculation has been performed. Random allocation was done by the sequentially sealed envelope method.

Interventions

Pre-operative preparation:

  • Scaling and root planning and delivering proper hygiene instructions.
  • Fabrication of the occlusal stent/radiographic guide (Silicone impression of the concerned arch and pouring of the model. Denture teeth are added on the edentulous space of the cast. A 2 mm thickness clear resin sheet is adapted to the cast with a vacuum forming machine. The borders of the stent are trimmed with a tungsten carbide bur to remove the parts that are covering the soft tissues. At the level of the surgical site, the intaglio of the guide is reduced in a way to prevent any interference with the swollen soft tissues during the one-week CBCT assessment. In the middle of each denture tooth, 2 mm cylindrical holes are created occlusally. Gutta-percha is inserted in these holes to serve as radio-opaque markers and as reference points for per-operative measurements.
  • Pre-operative Cone Beam CT (CBCTpreop) with the radiographic guide/occlusal stent in the mouth

Surgical intervention:

Patients are put on an antibiotic regimen consisting of 1 g co-amoxiclav taken twice daily (Augmentin, GlaxoSmithKline, Brentford, United Kingdom), starting the evening prior to surgery and continued for 10 days. For patients allergic to penicillins, Clindamycin 300 mg taken every 6 hours (Dalacin C, Pfeizer, New York City, NY, USA) is prescribed. Before surgery, the patient is asked to rinse with 0.12% chlorhexidine solution for one minute. Local anesthesia is delivered using 4% articaine with epinephrine 1:100,000 (Septanest, Septodont, Saint Maur des Fosses, France). After mid-crestal and vertical releasing incisions are being made, full thickness flaps are raised. The recipient bone is curetted to remove any soft tissue that may impede bone healing. Using a ridge mapping caliper, Crestal Bone Width is recorded at 1 (CBWpreop1), 3 (CBWpreop3) and 5 (CBWpreop5) mm from the crest at the level of the gutta-percha markers of the guide. Using a periodontal probe, another measure is recorded from the Ridge Crest to the Border of the Guide (RC-BG). This measure will be used at the 6-month re-entry to locate the vertical position of the pre-operative ridge mapping measurements in case of vertical bone changes. On the buccal flaps, superficial periosteal releasing incisions are performed to release the flap tension and to access the submucosal tissues. Once accessed, the submucosal tissues are stretched by inserting the wide end of a periosteal elevator into the incision line and pushing it in a coronal direction, resulting in flap elongation. In the posterior mandible, the lingual flap is elongated by a lateral stretching movement using the wide end of the periosteal elevator to separate the sub-mucosal tissues from the underlying muscle. More anteriorly in the mandible, a superficial periosteal incision is performed in the lingual flap. The buccal aspect of the crest is decorticated to ensure vascularization at the recipient site. The particulate bone graft consisting of a composite autograft-xenograft is then prepared in a 1:3 ratio mixed in sterile saline. A 0.5 cc spoon is used to have an exact 1:3 ratio. The spoon is slightly overfilled, and the excess is eliminated with a spatula. Only the full spoon content is used in the bone graft mix. The autograft is obtained by scraping the adjacent bony region with a bone scraper (SafeScraper TWIST, META, Reggio Emilia, Italy). The xenograft used is an anorganic bovine bone mineral with a 250-1000 microns particle size (OCS-B Xenomatrix®, Nibec, Chungcheongbuk-do, Korea, available also under the name of Straumann Xenograft® and Creos Xenogain®). After opening the sequentially sealed envelope, the patient is allocated to test or control groups. In the test group a glutaraldehyde cross-linked bovine collagen membrane GCLM is used (RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA), in the control group a non-cross-linked porcine skin collagen membrane is used (Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland). The membrane is fixed first on the buccal side with titanium pins (Masetrpin®, Meisinger, Neuss, Germany) in a way to create a pouch like space. Second, the composite graft is applied between the membrane and the crest with a slight over fill. Then the membrane is slightly stretched, wrapped over the ridge and tightly stabilized palatally/lingually with titanium pins. The graft-membrane complex should be completely immobile at finger pressure. A tight wound closure is achieved by placing a first line of horizontal mattress sutures followed by a second line of interrupted sutures along the horizontal incision. The vertical releasing incisions are closed with a combination of Laurel-Gottlow sutures and interrupted sutures. The sutures used are 4(0) PTFE monofilament sutures (Osteogenics Biomedical, Lubbock, TX, USA). Beside the antibiotic regimen described earlier, all patients are prescribed 0.12% chlorhexidine mouthwash (twice daily for 2 weeks, starting from the day after surgery), NSAIDs drugs (Bruffen 400mg every 6 hours, Abbott Laboratories, Illinois, CHI, USA) and/or paracetamol-opioid analgesics (Solpadeine, Omega Pharma Nazareth, Belgium). An extraoral cold pressure dressing is applied to minimize postoperative swelling. Sutures are removed 3 weeks after surgery.

During the first week after surgery, a Cone Beam CT (CBCTpostop) of the operated region is performed, with the radiographic guide in place.

Follow-up visits will be performed after 1, 3, 6, 10, 14, 18, 22 and 26 weeks.

Re-entry:

At 6 months post-surgery, another Cone Beam CT (CBCTre), with the same radiographic guide in place, is taken for bone volume assessment and for implant planning. Mid-crestal and vertical releasing incisions are made. Full thickness flaps are raised, and the pins are removed. Any non-integrated bone graft material is gently scraped and washed out with saline. The guide is put in place and using the previously recorded RC-BG measurement to correctly locate the level of the ridge crest before the ridge augmentation surgery, Crestal Bone Width is recorded with the ridge mapping caliper at the same locations (CBWre1, CBWre3, CBWre5) taken during the regeneration surgery. In addition, a UNC-15 periodontal probe is pushed with pressure against the ridge at a 45 degrees angle at the level of each gutta-percha marker and at 3 mm form the ridge top. The amount probe penetration in the grafted bone volume is recorded.

A 2 mm diameter trephine bone biopsy is collected for histomorphometrical and immunohistochemichal analysis. When possible, the biopsy is extracted horizontally from the buccal aspect of the ridge at 4 mm from the crest, otherwise it will be collected vertically from the ridge top. One biopsy is collected per patient, taken where the lateral ridge defect is the most severe.

Then the implants are inserted, at the prosthetically planned positions, according to the manufacturer's instructions. Flaps are sutured and a post-operative medication is prescribed consisting of an antibiotic coverage, an analgesic, and a chlorhexidine mouthwash.

Three months later, the implants are uncovered for abutment connection and will be subsequently restored.

Conditions
Bone Loss
Being tested
non-cross-linked porcine skin collagen membrane, glutaraldehyde cross-linked bovine collagen membrane
Keywords
Guided bone regeneration, collagen membrane, crosslinked collagen membrane, Bone augmentation
Medical subject headings
Bone Diseases, Metabolic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • non-cross-linked porcine skin collagen membraneOther

    Also called Bioguide

    non-cross-linked porcine skin collagen membrane used is Bioguide, Geistlisch Pharma AG, Wolhusen, Switzerland.

  • glutaraldehyde cross-linked bovine collagen membraneOther

    Also called Cytoplast RTM

    glutaraldehyde cross-linked bovine collagen membrane GCLM used is RTM Collagen®, Osteogenics Biomedical, Lubbock, TX, USA.

Study groups in NCT04402671
Study groupRoleWhat they receive
non-crosslinked collagen membrane groupActive comparator2 patients (1 male, 1 female)
Receives: Other: non-cross-linked porcine skin collagen membrane
glutaraldehyde cross-linked collagen membraneActive comparator2 patients (2 females)
Receives: Other: glutaraldehyde cross-linked bovine collagen membrane

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Linear measurements outcomes

    the ridge mapping changes in linear measurements between initial ridge width and reentry ridge width at 1, 3 and 5 mm from the ridge crest

    Measured: 6 - 9 months

Secondary outcomes (9)
  1. Volumetric measurements outcome

    Pre-operative Cone Beam CT (CBCTpreop), a Cone Beam CT the first week after surgery (CBCTpostop), and a Cone Beam CT at re-entry post-surgery (CBCTre), with the radiographic guide/occlusal stent in the mouth, are taken.

    DICOM files from the 3 CBCT scans are uploaded to the BlueSky Plan software (BlueSkyBio, Grayslake, IL, USA) and are superimposed using the gutta-percha markers of the radiographic guide. The Region Of Interest (ROI) is delineated Vpreop, Vpostop and Vre are the volume in cubic millimeters of the ROI measured from the CBCTpreop, CBCTpostop and the CBCTre, respectively.

    The volumetric outcomes from the DICOM data are used for each group to calculate:

    • the volume of graft resorption.
    • the graft volume created after GBR
    • the bone volume gain.

    Measured: 6 - 9 months

  2. the percentage of graft volume resorption.

    The percentage of graft volume resorption is calculated by deviding the volume of the graft resorbtion on the volume created after GBR

    Measured: 6 - 9 months

  3. Linear measurements outcomes on DICOM data

    On each gutta percha site on the DICOM files these measurements are assessed:

    Linear measurements in millimeters at 1, 3, 5 mm from the ridge crest in a plane orthogonally bisecting the dental arch at the level of each gutta-percha marker, taken form the ROI of CBCTpreop and CBCTre respectively.

    The changes of the linear measurements outcomes on DICOM data between CBCTpreop and CBCTre.

    Measured: 6 - 9 months

  4. Soft tissue healing

    Soft tissue healing will be assessed during the follow-up visits for the following occurrences Redness and swelling. Wound dehiscence and membrane exposure. Infections or any other unaccounted complications will be recorded

    Measured: 6 - 9 months

  5. Periodontal Probe Penetration (PP)

    PP reflecting the amount of graft maturation is recorded and compared between sites and between patients.

    Measured: 6 - 9 months

  6. Histology

    Histology analysis of the bone biopsies taken from the regenerated crests at re-entry surgery

    Measured: 6 - 9 months

  7. Histomorphometry: percentage of new bone formation

    Calculation of Percentage new bone formation in the bone biopsies taken from the regenerated crests at re-entry

    Measured: 6 - 9 months

  8. Histomorphometry: percentage of remaining graft particles

    Calculation of the percentage remaining graft particles in the bone biopsies taken from the regenerated crests at re-entry

    Measured: 6 - 9 months

  9. Histomorphometry: percentage of connective tissue

    Calculation of the percentage of connective tissue in the bone biopsies taken from the regenerated crests at re-entry

    Measured: 6 - 9 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 May 2020
  2. Study start1 Mar 2019
  3. Primary completion1 Aug 2020
  4. Study completion1 Aug 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
This study is a pilot randomized clinical trial with parallel groups, with an observation period of 6 - 9 months. It is set to identify the equivalence between the test and the control procedures. An equal randomization is set for the 2 groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
4 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04402671
Sponsor's protocol ID
FMD188
Status last verified
Oct 2020
First submitted
15 May 2020
Last updated
22 Oct 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All IPD that underlie results in a publication

Questions about this trial

What is this clinical trial studying?

A study testing non-cross-linked porcine skin collagen membrane and glutaraldehyde cross-linked bovine collagen membrane in people with Bone Loss, run by Saint-Joseph University at 1 site in Lebanon.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Lebanon. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Linear measurements outcomes (time frame: 6 - 9 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in